ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company confirmed that today the Annual Report and Accounts for the year ended 31 December 2016 has today been posted to..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today provided its final results for the twelve months ended 31 December 2016 (the “Period”). Key Highlights (including post..
ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy caught up with DirectorsTalk for an exclusive interview to discuss the latest update on their Phase III Lupuzor study Q1: Now Tim, ImmuPharma..
Immupharma Plc (LON:IMM) Chairman, Tim McCarthy talks to DirectorsTalk about its Lupuzor market update. Tim explains the main points to the update, the importance of reaching a milestone where all..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today provided an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced a proposed placing, raising a minimum of £3 million (before expenses), via the issue of new ordinary..
ImmuPharma PLC (LON:IMM) Non-Executive Chairman Tim McCarthy caught up with DirectorsTalk for an exclusive interview to discuss their Phase III Lupuzor trial; why the completion of patient recruitment on track..
Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview to discuss ImmuPharma PLC (LON:IMM) Q1: Now, we recently spoke about an AIM..
Immupharma Plc (LON:IMM) Non-Executive Chairman Tim McCarthy talks to DirectorsTalk about its phase 3 trial of Lupuzor. Tim explains the importance of completing the recruitment of the 200 patients and..
Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview to discuss ImmuPharma PLC (LON:IMM) Q1: Now Vadim, Northland have just been appointed..
Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk about the phase III trial update announced by Immupharma Plc (LON:IMM). Vadim talks us through the highlights and the..
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, have today provided further details of patient participation following confirmation (as announced on 22 December 2016) that the Company had..
